# US 2004/0062797 A1 · Release of therapeutic agents in a vessel or tissue

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0062797 A1
- Document ID: US20040062797A1
- Status: Published application
- Kind: A1
- Application number: 10/675,844
- Filed: 2003-09-30
- Published: 2004-04-01
- Earliest claimed: 2000-05-10
- Assignees: Trimedyne, Inc.
- Inventors: Marvin P. Loeb
- Web page: https://patentgrep.com/patent/US20040062797A1

## CPC

- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Particles larger than 7 microns in diameter and containing a therapeutic material are described. Such particles are sufficiently large to lodge in tissue or a blood vessel and can be made to rapidly degrade therein before creating infarcts. Rapid degradation of liposomes containing a therapeutic agent can be achieved by either preparing the liposome in a high salt solution or incorporating in the liposome a component which is stable at or below room temperature, but which becomes unstable at 35° C. or higher. Such particles are useful in delivering, for example, angiogenic growth factors or genes coding for angiogenic growth factors into the coronary arteries of the heart or the heart muscle, as well as other therapeutic agents into organs or tissues or blood vessels feeding the same to achieve a desired effect.

## Claims

### Claim 1

A physiologically compatible liposome containing at least one therapeutic agent; said liposome comprising dioleoylphosphatidylethanolamine, dipalmitoylphosphatidylcholine and cholesterol in a respective weight ration of about 7:3:5, having a diameter of at least about 7 microns but no more than about 300 microns, and a residence time in a body fluid of at least about one half-minute but less than about 3 minutes.

### Claim 2 (depends on 1)

The physiologically compatible particle in accordance with claim 1 wherein the therapeutic agent is hydrophilic.

### Claim 3 (depends on 1)

The physiologically compatible particle in accordance with claim 1 wherein the therapeutic agent is lipophilic.

### Claim 4 (depends on 1)

The physiologically compatible particle in accordance with claim 1 wherein the liposome contains a hydrophilic therapeutic agent and a lipophilic therapeutic agent.

### Claim 5 (depends on 1)

The physiologically compatible particle in accordance with claim 1 wherein the therapeutic agent is a biologically active substance.

### Claim 6 (depends on 5)

The physiologically compatible particle in accordance with claim 5 wherein the biologically active substance is a gene.

### Claim 7 (depends on 5)

The physiologically compatible particle in accordance with claim 5 wherein the biologically active substance is a protein.

### Claim 8 (depends on 5)

The physiologically compatible particle in accordance with claim 5 wherein the biologically active substance is an enzyme.

### Claim 9 (depends on 5)

The physiologically compatible particle in accordance with claim 5 wherein the biologically active substance is a monoclonal antibody.

### Claim 10 (depends on 5)

The physiologically compatible particle in accordance with claim 5 wherein the biologically active substance is a cytokine.

### Claim 11 (depends on 1)

The physiologically compatible particle in accordance with claim 1 wherein the therapeutic agent is a nutrient.

### Claim 12 (depends on 1)

The physiologically compatible particle in accordance with claim 1 wherein the therapeutic agent is a vitamin.

### Claim 13 (depends on 1)

The physiologically compatible particle in accordance with claim 1 wherein the therapeutic agent is a chemotherapeutic substance.

### Claim 14 (depends on 1)

The physiologically compatible particle in accordance with claim 1 wherein the therapeutic agent is an organic compound.

### Claim 15 (depends on 1)

The physiologically compatible particle in accordance with claim 1 wherein the therapeutic agent is an inorganic compound.

### Claim 16 (depends on 1)

The physiologically compatible particle in accordance with claim 1 wherein the therapeutic agent is bone marrow.

### Claim 17 (depends on 1)

The physiologically compatible particle in accordance with claim 1 wherein the therapeutic agent is a stem cell.

### Claim 18 (depends on 1)

The physiologically compatible particle in accordance with claim 1 wherein the therapeutic agent is fibroblast growth factor.

### Claim 19 (depends on 1)

The physiologically compatible particle in accordance with claim 1 wherein the therapeutic agent is vascular endothelial growth factor.

### Claim 20 (depends on 1)

The physiologically compatible particle in accordance with claim 1 which is a microsphere.

### Claim 21

A method for introducing a therapeutic agent into the vasculature of a patient which comprises injecting into a patient's blood stream physiologically compatible liposomes containing at least one therapeutic agent, which particles have a diameter of at least about 7 microns but no more than about 300 microns; said liposomes comprising dioleoylphosphatidylethanolamine, dipalmitoylphosphatidylcholine and cholesterol in a respective weight ratio of about 7:3:5 and having a residence time in the patient's blood stream of at least about one-half minute but less than about 3 minutes.

### Claim 22 (depends on 21)

The method in accordance with claim 21 wherein the physiologically compatible discrete particles are microspheres.

### Claim 23 (depends on 21)

The method in accordance with claim 21 wherein the therapeutic agent is hydrophilic.

### Claim 24 (depends on 21)

The method in accordance with claim 21 wherein the therapeutic agent is lipophilic.

### Claim 25 (depends on 21)

The method in accordance with claim 21 wherein the particles are liposomes that contain a hydrophilic therapeutic agent with a lipophilic therapeutic agent.

### Claim 26 (depends on 21)

The method in accordance with claim 21 wherein the therapeutic agent is a biologically active substance.

### Claim 27 (depends on 26)

The method in accordance with claim 26 wherein the biologically active substance is a gene.

### Claim 28 (depends on 26)

The method in accordance with claim 26 wherein the biologically active substance is a protein.

### Claim 29 (depends on 26)

The method in accordance with claim 26 wherein the biologically active substance is an enzyme.

### Claim 30 (depends on 26)

The method in accordance with claim 26 wherein the biologically active substance is a monoclonal antibody.

### Claim 31 (depends on 26)

The method in accordance with claim 26 wherein the biologically active substance is a cytokine.

### Claim 32 (depends on 21)

The method in accordance with claim 21 wherein the therapeutic agent is a nutrient.

### Claim 33 (depends on 21)

The method in accordance with claim 21 wherein the therapeutic agent is a vitamin.

### Claim 34 (depends on 21)

The method in accordance with claim 21 wherein the therapeutic agent is a chemotherapeutic substance.

### Claim 35 (depends on 21)

The method in accordance with claim 21 wherein the therapeutic agent is an organic compound.

### Claim 36 (depends on 21)

The method in accordance with claim 21 wherein the therapeutic agent is an inorganic compound.

### Claim 37 (depends on 21)

The method in accordance with claim 21 wherein the therapeutic agent is a stem cell.

### Claim 38 (depends on 21)

The method in accordance with claim 21 wherein the therapeutic agent is bone marrow.

### Claim 39 (depends on 21)

The method in accordance with claim 21 wherein the therapeutic agent is fibroblast growth factor.

### Claim 40 (depends on 21)

The method in accordance with claim 21 wherein the therapeutic agent is vascular endothelial growth factor.
